Conferences - Results from #9540

WCE 2017: Use of the Selective Cholesterol Absorption Inhibitor, Ezetimibe, and Subsequent Risk for Urolithiasis September 13, 2017

WCE 2017: Single Surgeon Experience with Revision of Ureteroenteric Anastomosis for Benign Strictures after Urinary Diversion September 13, 2017

WCE 2017: Arbutin as a novel prevention and therapy for calcium oxalate nephrolithiasis September 13, 2017

WCE 2017: Effect of Testosterone Impregnated Pellet Therapy on Lower Urinary Tract Symptoms September 13, 2017

WCE 2017: Role of Chaperone Proteins in Obstructed Renal Pelvis September 13, 2017

ESMO 2017: Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration September 13, 2017

ESMO 2017: Avelumab treatment of metastatic urothelial carcinoma in the phase 1b JAVELIN Solid Tumor study: Updated analysis with ≥6 months of follow-up in all patients September 13, 2017

ESMO 2017: Immunotherapy for Urothelial Cancer – Longer Follow-up and Subgroup Analyses: Invited Discussant September 13, 2017

ESMO 2017: 14 years of progress in mCRPC – New avenues for immunotherapy and precision medicine: Invited Discussant September 13, 2017

ESMO 2017: Prostate Cancer Poster Discussion: Invited Discussant September 13, 2017

ESMO 2017: Urothelial Carcinoma Poster Discussion – Invited Discussant September 13, 2017

ESMO 2017: Biological assessment of viable germ cell tumor in patients with seminoma and non-seminoma using miR371 September 13, 2017

ESMO 2017: Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma: Real world data from an Italian Expanded Access Program September 13, 2017

ESMO 2017: SPAZO2 (SOGUG): Validation of the International Metastatic Database Consortium prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib in metastatic renal cell carcinoma September 13, 2017

ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide September 13, 2017

ESMO 2017: Cabazitaxel followed by ADT improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A Randomized, Open Label, Phase III, Multicenter trial September 13, 2017

ESMO 2017: Assessment of health-related quality of life in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 vs 25 mg/m2 in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) September 13, 2017

ESMO 2017: Outcomes of patients with metastatic renal cell carcinoma who were treated with second-line vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line immune checkpoint inhibitor therapy September 13, 2017

ESMO 2017: Association between biopsychosocial distress and overall survival in patients with metastatic renal cell carcinoma September 13, 2017

ESMO 2017: SPAZO2 (SOGUG): Comparative effectiveness of everolimus vs axitinib as second-line after first-line pazopanib in metastatic renal carcinoma September 12, 2017

Page 478 of 624